R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia

被引：14
|
作者：
Tonino, S. H. [1 ,2 ]
van Gelder, M. [3 ]
Eldering, E. [2 ]
van Oers, M. H. [1 ]
Kater, A. P. [1 ]
机构：
[1] Univ Amsterdam, Acad Med Ctr, Dept Hematol, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands
[3] Maastricht Univ, Med Ctr, Dept Hematol, Maastricht, Netherlands
来源：
LEUKEMIA | 2010年 / 24卷 / 03期
关键词：
OXALIPLATIN;
D O I：
10.1038/leu.2009.240
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：652 / 654
页数：4
相关论文
共 50 条
  • [21] The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy
    Tam, Constantine S.
    O'Brien, Susan
    Lerner, Susan
    Khouri, I.
    Ferrajoli, A.
    Faderl, S.
    Browning, M.
    Tsimberidou, Apostolia M.
    Kantarjian, Hagop
    Wierda, William G.
    LEUKEMIA & LYMPHOMA, 2007, 48 (10) : 1931 - 1939
  • [22] A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia
    Frankel, AE
    Fleming, DR
    Hall, PD
    Powell, BL
    Black, JH
    Leftwich, C
    Gartenhaus, R
    CLINICAL CANCER RESEARCH, 2003, 9 (10) : 3555 - 3561
  • [23] MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
    Manuela Ferracin
    Barbara Zagatti
    Lara Rizzotto
    Francesco Cavazzini
    Angelo Veronese
    Maria Ciccone
    Elena Saccenti
    Laura Lupini
    Andrea Grilli
    Cristiano De Angeli
    Massimo Negrini
    Antonio Cuneo
    Molecular Cancer, 9
  • [24] MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
    Ferracin, Manuela
    Zagatti, Barbara
    Rizzotto, Lara
    Cavazzini, Francesco
    Veronese, Angelo
    Ciccone, Maria
    Saccenti, Elena
    Lupini, Laura
    Grilli, Andrea
    De Angeli, Cristiano
    Negrini, Massimo
    Cuneo, Antonio
    MOLECULAR CANCER, 2010, 9
  • [25] Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia
    Wierda, William G.
    Kipps, Thomas J.
    Mayer, Jiri
    Robak, Tadeusz
    Dyer, Martin J. S.
    Eurman, Richard R.
    Hillmen, Peter
    Stilgenbauer, Stephan
    Williams, Catherine D.
    Trneny, Marek
    Cartron, Guillaume
    Hernandez-Ilizaliturri, Francisco J.
    Padmanabhan, Swaminathan
    Chan, Geoffrey W.
    Gupta, Ira V.
    Gorczyca, Michele M.
    Davis, Randy L.
    Losic, Nedjad
    Lisby, Steen
    Osterborg, Anders
    BLOOD, 2010, 116 (21) : 406 - 407
  • [26] Unusually swift response of relapsed Burkitt leukemia to R-DHAP
    Harrer, Dennis Christoph
    Denk, Alexander
    Keil, Felix
    Menhart, Karin
    Mayer, Stephanie
    Wolff, Daniel
    Edinger, Matthias
    Herr, Wolfgang
    Grube, Matthias
    EJHAEM, 2022, 3 (03): : 1003 - 1008
  • [27] THE NATURAL HISTORY OF FLUDARABINE-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WHO FAIL ALEMTUZUMAB OR HAVE BULKY LYMPHADENOPATHY - A EUROPEAN PERSPECTIVE
    De Cock, E.
    Haiderali, A.
    Wasiak, R.
    Lis, Y.
    Levy, V
    VALUE IN HEALTH, 2011, 14 (07) : A456 - A456
  • [28] Activity of ofatumumab, a novel CD20 mAb, and prior rituximab exposure in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia (CLL)
    Wierda, W. G.
    Kipps, T.
    Mayer, J.
    Stilgenbauer, S.
    Robak, T.
    Williams, C. D.
    Furman, R.
    Chan, G.
    Russell, C.
    Osterborg, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Clinical improvement with a novel CD20 mAb, ofatumumab, in fludarabine-refractory chronic lymphocytic leukemia (CLL) also refractory to alemtuzumab or with bulky lymphadenopathy
    Kipps, T. J.
    Osterborg, A.
    Mayer, J.
    Stilgenbauer, S.
    Hellmann, A.
    Williams, C. D.
    Furman, R.
    Chan, G.
    Russell, C.
    Wierda, W. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia
    Tsimberidou, Apostolia M.
    Wierda, William G.
    Plunkett, William
    Kurzrock, Razelle
    O'Brien, Susan
    Wen, Sijin
    Ferrajoli, Alessandra
    Ravandi-Kashani, Farhad
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Kipps, Thomas J.
    Brown, Jennifer R.
    Fiorentino, Albert
    Lerner, Susan
    Kantarjian, Hagop M.
    Keating, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) : 196 - 203
12345